OCUP — Ocuphire Pharma Cashflow Statement
0.000.00%
Last trade - 00:00- $51.59m
- $4.42m
- $19.05m
- 32
- 35
- 37
- 27
Annual cashflow statement for Ocuphire Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -8.64 | -24.6 | -56.7 | 17.9 | -9.99 |
| Depreciation | |||||
| Non-Cash Items | -1.91 | 16.7 | 37.1 | 1.98 | 4.79 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.225 | 1.15 | 0.181 | -5.55 | 4.08 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -10.3 | -6.8 | -19.4 | 14.3 | -1.11 |
| Capital Expenditures | -0.019 | 0 | — | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 3.12 | 0.539 | -0.1 | 0 | 0 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 3.1 | 0.539 | -0.1 | 0 | 0 |
| Financing Cash Flow Items | 0 | 19.4 | -1.62 | -0.131 | -0.278 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 7.65 | 21.1 | 27.6 | 3.79 | 8.98 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.475 | 14.9 | 8.13 | 18.1 | 7.87 |